A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Opus Genetics, Inc. (the “Company,” “Opus,” “we,” “us,” or “our”) is a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (“IRDs”) and other types of therapies for additional ophthalmic disorders. Opus was founded in February 2018 as Ocuphire Pharma, Inc. and has since undergone the following transactions: In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution. Opus Genetics, Inc. Form 10-K In January 2020, Ocuphire Pharma, Inc. obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1 inhibitor program, including APX3330. In November 2020, Ocuphire Pharma, Inc. completed a reverse merger into Rexahn Pharmaceuticals, Inc.
| Segment | 2022 | % of Total |
|---|---|---|
License Transfer Fee | $40M | 99% |
Research and Development Services | $0M | 1% |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 15M | - | 19M | 40M | - | 0 |
| Net Income | -68M | -58M | -10.0M | 18M | -57M | -25M |
| EPS | $-1.86 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 |
| Free Cash Flow | 0 | -26M | -1.1M | 14M | -19M | -6.8M |
| ROIC | -142.5% | -729.3% | -20.0% | 503.7% | -68.8% | -89.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.18 | 1.68 | 0.01 | 0.00 | 0.02 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -65M | -62M | -11M | 18M | -23M | -20M |
| Operating Margin | -445.4% | - | -55.5% | 45.7% | - | - |
| ROE | -1143.0% | -203.2% | -20.0% | 38.7% | -255.1% | - |
| Shares Outstanding | 69M | 27M | 45M | 21M | 15M | 19M |
Opus Genetics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -16.9%.
Opus Genetics, Inc. (IRD) has a 5-year average return on invested capital (ROIC) of -59.3%. This is below average and may indicate limited pricing power.
Opus Genetics, Inc. (IRD) has a market capitalization of $383M. It is classified as a small-cap stock.
Opus Genetics, Inc. (IRD) does not currently pay a regular dividend.
Opus Genetics, Inc. (IRD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Opus Genetics, Inc. (IRD) generated $-26 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Opus Genetics, Inc. (IRD) has a debt-to-equity ratio of 1.68. This indicates higher leverage, which may increase financial risk.
Opus Genetics, Inc. (IRD) reported earnings per share (EPS) of $-2.15 in its most recent fiscal year.
Opus Genetics, Inc. (IRD) has a return on equity (ROE) of -203.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for Opus Genetics, Inc. (IRD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Opus Genetics, Inc. (IRD) has a book value per share of $0.25, based on its most recent annual SEC filing.